Understanding Who Shouldn’t Take Ozempic for Weight Loss

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (a GLP-1 receptor agonist) has helped millions lose weight, but it carries absolute contraindications and relative cautions that make it inappropriate for specific patient populations. The FDA approval for weight loss came in 2021, yet many people overlook critical medical factors that determine safety and efficacy for their individual situation.

Absolute Contraindications to Semaglutide Use

Certain medical conditions completely rule out semaglutide therapy. Personal or family history of medullary thyroid carcinoma (MTC)—a rare thyroid cancer—is the strongest absolute contraindication, because animal studies showed GLP-1 agonists may promote thyroid C-cell tumors. Patients with a history of multiple endocrine neoplasia syndrome type 2 (MEN2) also cannot safely receive semaglutide, as this genetic condition increases MTC risk substantially.

Severe hypersensitivity or documented allergic reactions to semaglutide or any component of the injection formulation represent another absolute barrier. Additionally, patients with active or recent pancreatitis should avoid GLP-1 therapy, since the drug class can theoretically trigger or worsen pancreatic inflammation, though causation remains debated in clinical literature.

Pregnancy, Breastfeeding, and Reproductive Considerations

Semaglutide is classified as a Category C medication for pregnancy, meaning animal reproduction studies have shown adverse effects, but human data remain limited. Women actively trying to conceive or currently pregnant should not take semaglutide, as the drug may affect fetal development. Most prescribing guidelines recommend stopping semaglutide at least two months before attempting conception to allow the body to clear the medication.

Breastfeeding mothers face similar restrictions because semaglutide may pass into breast milk at unknown concentrations. Women on semaglutide who become pregnant unexpectedly should contact their prescriber immediately rather than abruptly stopping the medication, as withdrawal carries its own risks. PlexusDx recommends discussing reproductive plans during your initial consultation to ensure alignment with treatment timing.

Kidney Disease and Severe Liver Dysfunction

Patients with severe renal impairment (eGFR below 15 mL/min/1.73m²) require careful evaluation before starting semaglutide, as the kidneys help clear the medication. While semaglutide doesn't undergo hepatic metabolism, patients with end-stage liver disease or decompensated cirrhosis may experience unpredictable drug handling and should be excluded from treatment. Moderate kidney or liver disease doesn't automatically contraindicate semaglutide, but close monitoring becomes essential.

Dehydration risk increases in patients with preexisting kidney issues, especially when combined with semaglutide-induced nausea and reduced appetite. Those on dialysis or with a history of kidney transplant should consult their nephrologist and prescribing physician before initiating GLP-1 therapy, as individual risk-benefit calculations vary widely.

Diabetic Retinopathy, Thyroid Concerns, and Recent Surgery

Patients with non-proliferative diabetic retinopathy face increased risk of vision problems when semaglutide causes rapid blood-sugar drops, particularly if they've had little glycemic control previously. Those with known thyroid nodules or abnormal thyroid function tests should undergo thyroid evaluation before starting semaglutide, since the drug's effects on thyroid tissue remain incompletely understood in some populations. A baseline TSH and thyroid ultrasound may be prudent in these cases.

Recent gastrointestinal surgery (within three months) is a relative contraindication because semaglutide slows gastric emptying, potentially causing complications like obstruction or infection at surgical sites. Patients with a history of gastroparesis (delayed stomach emptying) should avoid semaglutide entirely, as the drug exacerbates this condition. Those considering weight-loss surgery should pause semaglutide therapy before the procedure and consult their surgical team on timing.

How PlexusDx Ensures Safe Semaglutide Prescription

The PlexusDx Precision Peptide Genetic Test ($298) analyzes MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Compounded semaglutide from licensed 503A pharmacies undergoes rigorous quality control and sterility testing before shipment. PlexusDx's pharmacists review contraindications and relative cautions for every patient, ensuring your dose starts low and escalates only if medically appropriate. Monthly pricing remains flat at $149/mo regardless of dose adjustment, so your dose may go up but your price won't—removing barriers to safe, personalized care.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can someone with a family history of thyroid cancer take semaglutide?

If a first-degree relative had medullary thyroid carcinoma or you carry a MEN2 genetic mutation, semaglutide is contraindicated. Other thyroid cancers don't automatically exclude you, but your prescriber will evaluate your individual risk and may order baseline thyroid imaging. PlexusDx reviews family history in detail during intake to protect your safety.

Is semaglutide safe if I have type 2 diabetes and kidney disease?

Moderate kidney disease doesn't necessarily exclude semaglutide, but severe renal impairment (eGFR <15) requires specialist consultation. GLP-1 agonists may reduce kidney strain by lowering blood pressure and glucose, but dehydration risk increases. Your PlexusDx provider will assess your kidney function labs and coordinate care with your nephrologist before starting therapy.

What if I want to become pregnant while on semaglutide?

Semaglutide should be stopped at least two months before attempting conception due to limited human pregnancy data and animal studies showing potential fetal effects. If you're planning a family, discuss timing with your PlexusDx prescriber so you can transition to safe alternatives or pause therapy appropriately. Unplanned pregnancy while on semaglutide requires immediate provider contact—don't stop abruptly.

Can I take semaglutide if I've had pancreatitis before?

History of acute pancreatitis is a relative caution; you may be a candidate if the episode was clearly non-drug-related and resolved fully, but your prescriber must evaluate risk carefully. Chronic pancreatitis or unexplained abdominal pain typically excludes GLP-1 therapy. PlexusDx gathers detailed gastrointestinal history to determine if semaglutide is appropriate for your situation.

How does the Precision Peptide Genetic Test help identify safety risks?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.